Breast Cancer Clinical Trial
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in subjects with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Locally advanced or metastatic solid tumor malignancies that have relapsed or progressed after at least one line of therapy and where the following anti-PD-L1 are approved: avelumab, atezolizumab or durvalumab
Capable of giving signed informed consent
Aged ≥ 18 years old
Willingness to comply with study procedures and duration
Measurable disease per iRECIST
Contraceptive use for women and men as defined in the protocol
Pregnant or breast-feeding women
ECOG performance status ≥ 2
Evidence of insufficient organ function
Clinically significant cardiovascular disease
Receipt of therapy within 2 weeks prior to Day 1 or five half-lives, whichever is shorter or any investigational therapy within 28 days prior to Day 1
Known active central nervous system (CNS) involvement by malignancy
Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis or neurodegenerative disease or receipt of medications for these conditions
Currently receiving or likely to require immunosuppressive therapy
Known active infections with Hepatitis B, Hepatitis C or HIV
Live vaccine within 6 weeks prior to start of lympho-conditioning
Known allergy to albumin (human) or DMSO
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
Minneapolis Minnesota, 55455, United States
Hackensack New Jersey, 07601, United States
Houston Texas, 77030, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.